Is this you? Create Your Porfile
Avatar

Chris Barnes

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Chris Barnes is active.

Explore More

Publication

Featured researches published by Chris Barnes.

Chest | 2016

Trial in Progress: A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Trial to Evaluate the Safety and Tolerability of a Nebulized Long-Acting Muscarinic Antagonist (Revefenacin) in Study Participants With COPD

Luis Delacruz; Srikanth Pendyala; Chris Barnes; Edmund Moran; Brett Haumann; Gregory Feldman

Chest | 2016

Trials in Progress: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Trials of a Nebulized Long-Acting Muscarinic Antagonist (Revefenacin) in Study Participants With Moderate to Very Severe COPD

Krishna Pudi; Srikanth Pendyala; Chris Barnes; Edmund Moran; Brett Haumann; Edward Kerwin

Respiratory Research | 2017

A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease

Krishna Pudi; Chris Barnes; Edmund Moran; Brett Haumann; Edward Kerwin

Chest | 2018

EFFICACY OF REVEFENACIN, A LONG-ACTING MUSCARINIC ANTAGONIST FOR NEBULIZED THERAPY, IN COPD PATIENTS WITH MARKERS OF MORE SEVERE DISEASE

James F. Donohue; Edward Kerwin; Chris Barnes; Edmund Moran; Brett Haumann; Srikanth Pendyala; Glenn Crater

Chest | 2018

CARDIOVASCULAR SAFETY OF REVEFENACIN FOR NEBULIZATION: A REVIEW OF RANDOMIZED CONTROLLED TRIAL DATA

James F. Donohue; Gregory Feldman; Sanjay Sethi; Marie Borin; Chris Barnes; Borje Darpo; Srikanth Pendyala; David L. Bourdet

Chest | 2018

EFFICACY OF REVEFENACIN BY NEBULIZATION AND TIOTROPIUM BY HANDIHALER IN SUBJECTS WITH COPD AND SUBOPTIMAL PEAK INSPIRATORY FLOW RATES (PIFR)

Donald A. Mahler; Jill Ohar; Chris Barnes; Edmund Moran; Srikanth Pendyala; Glenn Crater

European Respiratory Journal | 2017

Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD

Gary T. Ferguson; Krishna Pudi; Gregory Feldmann; Srikanth Pendyala; Chris Barnes; Edmund Moran; Glenn Crater; Brett Haumann

Chest | 2017

The 24-Hour Profile of FEV1 After 12-Weeks Treatment With Revefenacin, a Once Daily Long-Acting Muscarinic Receptor Antagonists for Nebulization: A Spirometry Substudy

James F. Donohue; Srikanth Pendyala; Chris Barnes; Edmund Moran; Glenn Crater

Chest | 2017

Improvements in Health Status With Revefenacin, a Once-Daily Long-Acting Muscarinic Antagonist for Nebulization: Changes in St George’s Respiratory Questionnaire and COPD Assessment Test in Replicate 3-Month Studies

James F. Donohue; Srikanth Pendyala; Chris Barnes; Edmund Moran; Glenn Crater

Chest | 2016

Nebulized Revefenacin Results in a Reduction in the Daily Use of Rescue Medication: Results From a 28-Day Study in Participants With COPD

Krishna Pudi; Chris Barnes; Edmund Moran; Brett Haumann; Edward Kerwin

Explore More

Collaboration

Dive into the Chris Barnes's collaboration.

Top Co-Authors
Avatar

Brett Haumann

GlaxoSmithKline

View shared research outputs
Top Co-Authors
Avatar

Glenn Crater

GlaxoSmithKline

View shared research outputs
Top Co-Authors
Avatar

Edward Kerwin

Research Triangle Park

View shared research outputs
Top Co-Authors
Avatar

James F. Donohue

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors
Avatar

Gregory Feldman

Medical Park

View shared research outputs
Top Co-Authors
Avatar

David L. Bourdet

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors
Avatar

Donald A. Mahler

Dartmouth College

View shared research outputs
Top Co-Authors
Avatar

Gary T. Ferguson

Wayne State University

View shared research outputs
Top Co-Authors
Avatar

Sanjay Sethi

State University of New York System

View shared research outputs
Top Co-Authors
Avatar

Jill Ohar

Saint Louis University

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge